Infant formula supplemented with probiotics reduces gastrointestinal infections' rate in day care infants

Weizman, Zvi; Asli, Ghaleb; Alsheikh, Ahmed

doi:10.1016/s0261-5614(03)80257-1

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is thus reason to believe that these bacteria normally play a role in the colonization of the human infant. Clinical trials in infants and young children have confirmed that L. reuteri also confer real health benefit (e.g., in preventing gastrointestinal infection in day care centers (27) and in treating acute diarrhea (28,29)).…”

Section: Resultsmentioning

confidence: 99%

Safety of D(‐)‐Lactic Acid Producing Bacteria in the Human Infant

Connolly

Abrahamsson²,

Björkstén³

2005

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Safety of D(‐)‐Lactic Acid Producing Bacteria in the Human Infant

Connolly

Abrahamsson²,

Björkstén³

2005

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

“…In other studies the effect of the strain on clinical symptoms in different clinical conditions (acute diarrhoea, irritable bowel syndrome, infant colic, constipation, reduction of gingivitis and lowering infections rate) was evaluated (Tubelius et al, 2005;Niv et al, 2005;Ouweland etal., 2002;Ruiz-Palacios et al, 1996;Savino et al, 2005 andal., 2007;Shornikova et al,,1997a and1997b;Weizman et al, 2003 andGuerrero et al, 1996;Krasse et al, 2006). The Panel notes that these studies do not address the claimed effect.…”

Section: Scientific Substantiation Of the Claimed Effectmentioning

confidence: 99%

Scientific Opinion on the substantiation of health claims related to Lactobacillus reuteri ATCC 55730 and decreasing potentially pathogenic intestinal microorganisms (ID 904) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

Products¹

2009

EFSA Journal

View full text Add to dashboard Cite

Scientific Opinion on the substantiation of health claims related to Lactobacillus reuteri ATCC 55730 and decreasing potentially pathogenic intestinal microorganisms (ID 904) pursuant to Article 13(1) of Regulation SUMMARY Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of Regulation 1924Regulation /2006. This opinion addresses the scientific substantiation of health claims in relation to Lactobacillus reuteri ATCC 55730 and decreasing potentially pathogenic intestinal microorganisms. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders.The food constituent that is the subject of the health claim is Lactobacillus reuteri ATCC 55730. The Panel considers that Lactobacillus reuteri ATCC 55730 is sufficiently characterised.The claimed effect "intestinal flora" is not sufficiently defined but in the context of the proposed wording, the Panel assumes that the claimed effect refers to aspects of: "probiotic, beneficially affect the intestinal flora, support a healthy intestinal flora, and balance intestinal flora". The Panel considers that decreasing potentially pathogenic intestinal microorganisms might be beneficial to human health.

show abstract

Infant formula supplemented with probiotics reduces gastrointestinal infections' rate in day care infants

Cited by 2 publications

References 0 publications

Safety of D(‐)‐Lactic Acid Producing Bacteria in the Human Infant

Safety of D(‐)‐Lactic Acid Producing Bacteria in the Human Infant

Scientific Opinion on the substantiation of health claims related to Lactobacillus reuteri ATCC 55730 and decreasing potentially pathogenic intestinal microorganisms (ID 904) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

Contact Info

Product

Resources

About